In an era where digital technologies are becoming ubiquitous, especially among aging populations, a study published in Nature ...

The study reveals that AI systems offer promising accuracy in predicting treatment outcomes, particularly when used to ...

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory ...

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such ...

While many studies have focused on generating high-fidelity synthetic images for beneficial applications, very few have ...

Higher cumulative heart health score from age 18 to 45 years was associated with lower risk for cardiovascular disease and ...

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with ...

Johnson & Johnson MedTech announced positive three-month results from a study evaluating its investigational Omnypulse ...